trality and percentages determined. RESULTS: The data reveal a 100% written diagnosis for all prescriptions encountered. There were more females than males (70% vs 30%). The average number of drugs per prescription was 6.0. About 61% of the diabetic patients were also diagnosed with hypertension. Biguanides (95%) were the commonest oral hypoglycaemic agent prescribed while calcium channel antagonist (60%) was the commonest antihypertensive prescribed. The average cost of medication per prescription was GHC 40.0 (Ghana cedi) -approx $20.5 (USD), were as the average total cost of drugs per patient for the entire year was GHC 235.2 (Ghana cedi) -approx $120 (USD) CONCLUSIONS: The study demonstrates that most patients attending the diabetic clinic in Ho Municipal Hospital are females. The cost of diabetic medications to patient per prescription was expectedly high, particularly due to the high number of drugs prescribed. Most diabetic patients have hypertension. The prescription of ACE-I therefore need to be improved to reduce the rate of cardiovascular complication in diabetes.
OBJECTIVES:
One of the main causes of premature death and disability in diabetic patients are amputations of lower limbs which are the result of the development of diabetic foot syndrome (DFS) . Poland belongs to countries with a high rate of amputation. It is believed that the high rate of amputation is caused by significantly higher costs of DFS treatment compared to cost of amputation. Indeed, in Poland costs of DFS hospital treatment and amputation are almost equal. To answer the question whether the costs of DFS hospital treatment are overestimated this study estimated diabetic foot syndrome hospitalization costs based on data collected in the one of leading DFS treatment centers. METHODS: Data on hospitalization costs were estimated retrospectively, based on 2011 year disease documentation of all DFS patients treated in the Department of Gastroenterology and Metabolic Diseases of the Medical University of Warsaw. Values are presented in Euros (exchange rate: 1 EURϭ4.20 PLN). RESULTS: Data on 37 patients were analyzed. Total cost of hospitalization per patient was estimated at the amount of 1765 EUR and was almost 2-times higher than National Health Funds (NHF) reimbursement cost of hospitalization. However, it should be noted that most of the costs were related to bed costs (76%) which we believe are overestimated. The second cost position was drug costs which accounted for only 11% of total costs. Other cost positions such as: bandage, laboratory tests, diagnostic procedures and specialized team help (i.e. anesthesia) amounted up to 4% of total cost. CONCLUSIONS: The reimbursement of diabetic foot syndrome treatment seems to be rather underestimated than overestimated. However we suppose cost data provided by the hospital department for calculation are overestimated on bed costs and underestimated at other positions especially on diagnostic procedures and bandage costs.
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BURDEN OF DISEASE ATTRIBUTABLE TO CLINICAL AND SUBCLINICAL HYPOTHYROIDISM IN THE SPANISH POPULATION
Crespo C 1 , Pérez-Alcántara F 1 , Polanco C 2 1 Oblikue Consulting, Barcelona, Spain, 2 Merck SL, Madrid, Spain OBJECTIVES: Subclinical hypothyroidism (SH) is typically defined as asymptomatic, characterized by slightly increased serum thyrotropin (TSH) levels and normal serum free thyroxine concentrations. SH is common among general population, especially in middle-aged women most often after menopause, and it is related to cardiovascular events. The objective of this analysis was to estimate burden of disease of SH and it's evolution to clinical hypothyroidism (CH) in Spain. METHODS: The recommended methodology by WHO for burden of disease studies was used in this analysis. Disability-adjusted life years (DALY), years of life lost (YLL), years life with disability (YLD) and mortality related to SH and CH were calculated based on the adjusted attributable fraction. Prevalence of risk factors in general population as well as HR, were obtained from literature review and official sources (CMBD, hospital mortality register). RESULTS: In Spain, the number of patients with SH and CH was estimated at 2,767,124. Among them, TSH concentrations ranged between 4.5-6.9 mUI/L in 1,949,820 patients; between 6.9-10 mUI/L in 539,988 patients and between 10-19.9 mUI/L in 278,317 patients. Every year, 12,608 cardiovascular events, 1,388 cardiac deaths and 30, 550 DALY (13, 124 YLL and 17, 426 YLD) would be attributable to SH. SH represented between 1.6-7.3% of cardiovascular DALY. CONCLUSIONS: Both the extensive socioeconomic burden of SH and the risk of developing clinical hypothyroidism and subsequent cardiovascular health risks among patients with SH is to be considered. This suggests the utility of SH screening for patients with risk factors, after assessing the efficiency of screening techniques. 
PDB34 ECONOMIC EVALUATION OF TREATING DIABETES PATIENTS ACCORDING TO GUIDELINES IN SOUTH-WESTERN ONTARIO, CANADA
OBJECTIVES:
In spite of the fact that primary care physicians are recommended to following evidence-based clinical guidelines for management of diabetes, no studies have currently evaluated the clinical and economic impact of following diabetes guidelines in Ontario. METHODS: To assess the short-and long-term impact of treating patients with type II diabetes according to the guidelines in South-western Ontario, two cohorts of newly diagnosed cases in 2002 were used. The first group included patients who were not treated according to guidelines during the diagnostic year and the two years after diagnosis. The second group consisted with individuals who were not treated according to the guidelines only during the first year but for the two subsequent years of their diagnosis they were treated to achieve the specified targets for HbA1c, blood pressure and lipid levels according to guidelines. The short-term impacts of intervention in clinical outcomes were calculated and were used to extrapolate to 40 years horizon using the Ontario Diabetes Economic Model (ODEM). For each cohort, the event rates for seven diabetes-related complications, the mean difference in cost, and expected quality-adjusted life-years (QALYs) were calculated based on baseline risk and 3-years following the intervention. RESULTS: Almost 500 individuals newly diagnosed with diabetes in 2002 were not treated according to guidelines during the first year following diagnosis. Of those 236 were treated according to guidelines in the second and third year following diagnosis and 259 individuals were not (the control cohort). A small difference has been observed between the cohorts in terms of intermediate outcomes as well as the lifetime predicted cumulative costs, QALYs, life expectancy and event rate. CONCLUSIONS: The results of this study indicated that treating patients to guidelines as used by physicians did not make an impact on the short and long-term outcomes associated with diabetes. 
PDB35 EVALUATION OF THE LONG TERM ECONOMIC IMPACT OF IMPROVING HBA1C IN TYPE 2 DIABETES PATIENTS IN SAUDI ARABIA
OBJECTIVES:
Evidence from the A1chieve study (an international, prospective, observational study of insulin analogs within routine clinical practice) suggests the glycemic control in type 2 diabetes patients in Saudi Arabia is poor. The aim of the current analysis was to investigate the long-term clinical and economic benefits of a 1% reduction in HbA1c in comparison with baseline levels for type 2 diabetes patients in the Saudi Arabian setting. METHODS: Long-term projections were made using the published and validated CORE Diabetes Model, over a 35-year time horizon. Patient characteristics were taken from the Saudi Arabian cohort of the A1chieve study. At baseline, mean (SD) patient age was 51(11) years, duration of diabetes 10(6) years and HbA1c 9.8(0)%. Following a 1% HbA1c reduction in the active arm, HbA1c was kept constant. Captured costs included concomitant medications and diabetes-related complications. Costs of antihyperglycemic treatment and adverse events were not included. Future costs and clinical outcomes were discounted at a rate of 3% per annum. Costs are presented in 2011 Saudi Arabian Riyals (SAR) and converted into Euros (EUR) (SAR 1 to EUR 0.2043). RESULTS: Improved glycemic control was associated with improved life expectancy by 0.71 years (10.08 versus 9.37 years). Furthermore, reduction in HbA1c was associated with increased time free from diabetes-related complications. Direct costs were SAR 16,084 (EUR 3,286) lower in the reduced HbA1c group (SAR 173, 514 [EUR 35, 449] versus SAR 189,598 [EUR 38,735]). This was driven by savings resulting from the reduced incidence of complications. CONCLUSIONS: Baseline glycemic control in A1chieve type 2 diabetes patients in Saudi Arabia is sub-optimal. Improvements in A499 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
HbA1c are likely to lead to substantial clinical and economic benefits, driven by reduced complication rates. The cost-effectiveness of interventions designed to improve glycemic control in Saudi Arabia is worthy of investigation.
PDB36 AN EVALUATION OF THE LONG-TERM COSTS AND EFFECTS OF A 1% REDUCTION IN HBA1C IN TYPE 2 DIABETES PATIENTS IN MALAYSIA
Shafie AA 1 , Kareem F 2 , Hussein Z 3 , Smith-palmer J 4 , Hunt B 4 , Todorova L 5 1 Universiti Sains Malaysia, Penang, Malaysia, 2 Novo Nordisk International Operations, Selangor, Malaysia, 3 Hospital Putrajaya, Putrajaya, Malaysia, 4 Ossian Health Economics and Communications, Basel, Switzerland, 5 Novo Nordisk International Operations, Zurich, Switzerland OBJECTIVES: A1chieve is a prospective, international, observational study of basal, bolus and biphasic insulin analogues in routine clinical practice. The present analysis aimed to evaluate the economic and clinical benefits associated with a 1% reduction in HbA1c (relative to no change in HbA1c) in Malaysian A1chieve patients. METHODS: Life expectancy, complication rate and the cost of complications were projected over a 35-year time horizon using the published CORE Diabetes Model. At baseline, the mean (standard deviation) age of the cohort was 54 years (11 years), duration of diabetes was 12 (8) years, HbA1c was 10% (1.8%) and body mass index was 28.1 (5.1) kg/m2. HbA1c was reduced by 1%-point in the active group versus the control group. Costs were reported in 2011 Malaysian Ringgits (MYR) and converted to 2011 Euros (EUR) using the mid-market exchange rate on June 30, 2011. Future costs and clinical outcomes were discounted annually at a rate of 3.5%. RESULTS: A 1% reduction in HbA1c was associated with reduced costs of treating diabetes complications and an increase in life expectancy. Undiscounted life expectancy was improved by 0.36 years following HbA1c reduction (7.53 versus 7.17 years). The time alive and free of any diabetes complications increased from 0.31 years to 0.40 years in the HbA1creduction group. Over patient lifetimes, improved HbA1c was associated with cost savings of EUR 682 [MYR 3,067] (EUR 2, 745 [MYR 13, 607] versus EUR 3, 427 [MYR 16, 674] ). The greatest cost savings were associated with renal complications avoided. CONCLUSIONS: The A1chieve study has shown that glycemic control is generally poor in routine clinical practice in Malaysia. The present analysis showed that improved glycemic control would be likely to bring substantial clinical and economic benefits to these patients, arising primarily from reduced incidence of diabetes complications. 
PDB37
COST-EFFECTIVENESS OF ADDING TWICE-DAILY EXENATIDE TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES IN SCOTLAND
OBJECTIVES:
To estimate the long-term cost-effectiveness of adding twice-daily exenatide (BID) to basal insulin in patients with type 2 diabetes from the perspective of NHS Scotland. Data from GWCO, a phase III, double-blind, randomized, placebo-controlled trial, comparing the efficacy of adding exenatide BID to titrated insulin glargine versus titrated insulin glargine alone, was used for the modelling analysis. After 30 weeks, exenatide BID added to glargine was associated with greater mean HbA1c reduction (-1.71% vs. -1.00%, pϽ0.001) and weight reduction (-1.78 kg vs. ϩ0.96 kg, pϽ0.001) compared to glargine alone. METHODS: A previously published and validated diabetes model (IMS CORE Diabetes Model) was used to project 20-year clinical and cost outcomes based on the GWCO cohort (age 59 years, diabetes duration 12.3 years, HbA1c 8.41%) and efficacy and safety outcomes from the GWCO trial. Costs were derived from published sources and expressed in 2011 Pounds Sterling (£). An annual discount rate of 3.5% was applied to future costs and clinical benefits. RESULTS: In the base-case analysis exenatide BID plus glargine was projected to improve quality-adjusted life expectancy by 0.183 quality-adjusted life years (QALYs) and life expectancy by 0.147 years compared to glargine alone, at an additional cost of £1,721. The resulting cost per QALY was £9,411. Increased pharmacy costs were partially offset by reduced costs associated with diabetes complications with exenatide BID. Assuming a willingness-to-pay of £20,000 per QALY gained, exenatide BID had a 99.8% probability of being costeffective. Sensitivity analyses showed that results were robust to variation in range of model parameters. CONCLUSIONS: Based on results from GWCO clinical trial, exenatide BID plus glargine is projected to be a cost-effective use of NHS Scotland resources compared to glargine alone.
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COST-EFFECTIVENESS OF INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES IN ROMANIA
Ionescu-Targoviste C 1 , Wrona W 2 , Schubert A 3 , Niewada M 2 , Czech M 3 1 National Institute of Diabetes "Nicolae Paulescu", Bucharest, Romania, 2 HealthQuest Sp z o.o. Sp. k., Warsaw, Poland, 3 Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland OBJECTIVES: To assess cost-utility of switching type 2 diabetes patients to an insulin detemir-based regimen after failure to achieve adequate control on 1) oral antidiabetic agents (OADs) alone, or OAD in combination with 2) neutral protamine Hagedorn (NPH) insulin, or 3) insulin glargine in Romania. METHODS: The CORE Diabetes Model was used to model the long-term consequences. Efficacy results at the beginning and at the end of the study as well as baseline demographics of the patient cohort (subgroup analysis of the German cohort of PREDICTIVE study) were used. The perspective was the health care services payer over life time (35-years) . The analysis used model default health state utility values. Cost data were derived from DRG Data from the Center for Research and Evaluation of Healthcare Services (Romania), CaNaMed National Catalogue of Medicines Prices (official tariff lists) and expert opinion. RESULTS: In the 1st analysis (insulin detemir Ϯ OADs vs. OADs) QALYs increased by 0.399 years with insulin detemir. Total lifetime costs increased by EUR 4,413 resulting in an incremental cost per QALY gained of EUR 11,050. In the 2nd analysis insulin detemir increased quality-adjusted life expectancy by 0.394 QALYs and total costs by EUR 2,340, with incremental cost per QALY gained of EUR 5,943. Transferring from insulin glargine Ϯ OADs to insulin detemir Ϯ OADs (3rd analysis) increased QALYs by 0.319 years. Total costs increased by EUR 689 resulting in an incremental cost per QALY gained of EUR 2,160. CONCLUSIONS: Based on efficacy data from an observational study and a validated health economics model, insulin detemir was cost effective when compared to OAD alone, or insulin NPH Ϯ OAD, or insulin glargine Ϯ OAD for the treatment of type 2 diabetes in the Romanian health care setting.
